Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENEMID vs SODIUM BICARBONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Sodium bicarbonate dissociates to provide bicarbonate ion, which buffers excess hydrogen ions in the blood, increasing p H and reversing acidosis.
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
Treatment of metabolic acidosis,Cardiac arrest associated with hyperkalemia or tricyclic antidepressant overdose,Alkalinization of urine to prevent nephrotoxicity from certain drugs (e.g., methotrexate, sulfonamides),Adjuvant in treatment of severe diarrhea (off-label),Treatment of distal renal tubular acidosis (off-label)
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
For metabolic acidosis: 50-150 m Eq intravenously over 4-8 hours, dose adjusted based on base deficit or serum bicarbonate. For cardiac arrest: 1 m Eq/kg intravenously initially, then 0.5 m Eq/kg every 10 minutes. For urinary alkalinization: 325-2000 mg orally every 6 hours, titrate to urine p H 7-8.
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
5-6 hours in normal renal function; prolonged in renal impairment (up to 15-20 hours)
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Sodium bicarbonate is not metabolized; it dissociates to bicarbonate and sodium. Bicarbonate is rapidly converted to carbon dioxide by carbonic anhydrase in erythrocytes and renal tubules, and CO2 is excreted via lungs.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: >99% as bicarbonate; minimal biliary/fecal elimination
Approximately 85-95% bound primarily to albumin
<1% (not significantly protein bound)
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
0.3-0.4 L/kg (distributes primarily in extracellular fluid)
Oral: >90%
Oral: ~100% (but rapid conversion to CO2 in stomach may reduce effective systemic absorption)
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
No specific dose adjustment required; monitor sodium and fluid status. In severe renal impairment (GFR <10 m L/min), use with caution due to risk of volume overload and metabolic alkalosis. Not removed by hemodialysis.
No specific guidelines; use with caution in severe hepatic impairment.
No dosage adjustment necessary for hepatic impairment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
Metabolic acidosis: 1-2 m Eq/kg intravenously over 1-2 hours, repeat based on blood gas. Cardiac arrest: 1 m Eq/kg intravenously initially, may repeat 0.5 m Eq/kg every 10 minutes. Urinary alkalinization: 1-2 m Eq/kg orally every 6 hours, adjust to urine p H.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
Use with caution due to increased risk of fluid overload and electrolyte imbalances. Start at lower end of dosing range and titrate based on response and renal function. Monitor serum sodium, bicarbonate, and renal function frequently.
No FDA black box warning.
In cardiac arrest, routine use is not recommended; may cause paradoxical intracellular acidosis, hyperosmolality, and decreased tissue oxygen delivery.
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Risk of metabolic alkalosis with excessive use,Fluid overload due to sodium content, especially in heart failure, renal impairment, or cirrhosis,Hypocalcemia and reduced ionized calcium leading to tetany,Extravasation risk; intravenous administration should be via central line for concentrated solutions,Monitor serum electrolytes, p H, and calcium during therapy
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Metabolic alkalosis,Respiratory alkalosis,Hypocalcemia (unless used to treat cardiac arrest),Severe pulmonary edema or hypertension,Patients losing chloride from vomiting or gastrointestinal suction
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
High-sodium foods may compound sodium load. Avoid excessive milk or dairy intake (risk of milk-alkali syndrome). Can interfere with iron absorption; take iron supplements 2 hours apart. No specific food restrictions beyond balanced diet.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Sodium bicarbonate is generally considered low risk. No evidence of teratogenicity. Use during pregnancy is acceptable if clinically indicated.
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
Sodium bicarbonate is excreted into breast milk in small amounts. M/P ratio is not established. Considered compatible with breastfeeding, but monitor infant for metabolic alkalosis risk.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, standard dosing is usually sufficient; titrate to acid-base balance.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Contains 119 m Eq sodium per 3.8 g (50 m Eq base). Use with caution in heart failure, hypertension, or renal impairment. Rapid infusion can cause hypernatremia, decreased ionized calcium, and tetany. Do not mix with calcium-containing solutions or in the same IV line as catecholamines. In metabolic acidosis, correct only partially (to p H 7.2) to avoid rebound alkalosis. Not first-line for cardiac arrest except in known hyperkalemia or overdose.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
Do not take with milk or dairy products as it may cause milk-alkali syndrome.,Avoid taking within 2 hours of other medications as it may affect absorption.,Do not use as an antacid for more than 2 weeks unless directed by a doctor.,Seek emergency care if you have severe stomach pain, vomiting, or blood in vomit/stool.,Monitor for signs of alkalosis: muscle twitching, hand tremor, confusion, slow breathing.,Inform your doctor if you have high blood pressure, heart failure, or kidney disease.
No interactions on record
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENEMID vs SODIUM BICARBONATE, answered by our medical review team.
BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. SODIUM BICARBONATE is a Alkalinizing Agent that works by Sodium bicarbonate dissociates to provide bicarbonate ion, which buffers excess hydrogen ions in the blood, increasing p H and reversing acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENEMID and SODIUM BICARBONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. The standard adult dose of SODIUM BICARBONATE is: For metabolic acidosis: 50-150 m Eq intravenously over 4-8 hours, dose adjusted based on base deficit or serum bicarbonate. For cardiac arrest: 1 m Eq/kg intravenously initially, then 0.5 m Eq/kg every 10 minutes. For urinary alkalinization: 325-2000 mg orally every 6 hours, titrate to urine p H 7-8.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENEMID and SODIUM BICARBONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. SODIUM BICARBONATE is classified as Category A/B. Sodium bicarbonate is generally considered low risk. No evidence of teratogenicity. Use during pregnancy is acceptable if clinically indicated.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.